Literature DB >> 2322301

Inhibition of ox brain glutamate dehydrogenase by perphenazine.

I Couée1, K F Tipton.   

Abstract

Factors affecting the inhibition of ox brain glutamate dehydrogenase (GDH) by the antipsychotic drug perphenazine have been studied. Inhibition was found to be of mixed type with respect to 2-oxoglutarate and competitive towards NADH. However, the data indicate that perphenazine binds to a site distinct from the catalytic site to which NADH binds. Perphenazine also enhanced the high-substrate inhibition by these two substrates. Inhibition by perphenazine was not affected by the allosteric effector GTP but it was enhanced by increasing pH, in the range of 6.3 to 7.6, and diminished by increasing ionic strength. Low concentrations of perphenazine relieved the inhibition of GDH by phosphatidylserine and cardiolipin. However, at higher concentrations phosphatidylserine did not interfere with the inhibition by perphenazine whereas cardiolipin relieved it. The possible significance of these interactions in terms of the behaviour of this antipsychotic drug in vivo are discussed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2322301     DOI: 10.1016/0006-2952(90)90258-m

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  3 in total

1.  The sulphydryl groups of ox brain and liver glutamate dehydrogenase preparations and the effects of oxidation on their inhibitor sensitivities.

Authors:  I Couée; K F Tipton
Journal:  Neurochem Res       Date:  1991-07       Impact factor: 3.996

2.  Mapping the Intramolecular Communications among Different Glutamate Dehydrogenase States Using Molecular Dynamics.

Authors:  Shaherin Basith; Balachandran Manavalan; Tae Hwan Shin; Gwang Lee
Journal:  Biomolecules       Date:  2021-05-27

3.  Using Cryo-EM to Map Small Ligands on Dynamic Metabolic Enzymes: Studies with Glutamate Dehydrogenase.

Authors:  Mario J Borgnia; Soojay Banerjee; Alan Merk; Doreen Matthies; Alberto Bartesaghi; Prashant Rao; Jason Pierson; Lesley A Earl; Veronica Falconieri; Sriram Subramaniam; Jacqueline L S Milne
Journal:  Mol Pharmacol       Date:  2016-04-01       Impact factor: 4.436

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.